• Low β2-adrenergic receptor level may promote development of castration resistant prostate cancer and altered steroid metabolism 

      Braadland, Peder; Grytli, Helene Hartvedt; Ramberg, Håkon Andre; Katz, Betina; Kellmann, Ralf; Fazli, Ladan; Krobert, Kurt Allen; Wang, Wanzhong; Levy, Finn Olav; Bjartell, Anders; Berge, Viktor; Rennie, Paul S.; Mellgren, Gunnar; Mælandsmo, Gunhild; Svindland, Aud; Tasken, Kristin Austlid; Gauthier-Landry, Louis; Barbier, Olivier (Journal article; Tidsskriftartikkel; Peer reviewed, 2016)
      The underlying mechanisms responsible for the development of castration-resistant prostate cancer (CRPC) in patients who have undergone androgen deprivation therapy are not fully understood. This is the first study to address whether β2-adrenergic receptor (ADRB2)- mediated signaling may affect CRPC progression in vivo. By immunohistochemical analyses, we observed that low levels of ADRB2 is associated ...